Category: Therapeutics

Greetings, dear readers! Today, let’s dive into the fascinating realm of stability testing for protein therapeutics using Dynamic Light Scattering (DLS). In the fast-paced world of biopharmaceuticals, ensuring the stability of protein-based drugs is paramount to their efficacy and safety. The utilization of cutting-edge techniques such as DLS plays a crucial role in this process, […]

Welcome to the world of microbiome research, a realm where the intricate interplay between microbial communities and human health takes center stage. The human microbiome plays a pivotal role not only in sustaining health but also in the onset and progression of various diseases. At the forefront of scientific inquiry are preclinical and clinical investigations […]

Nanotechnology has sparked a revolution in the field of therapeutics, offering innovative solutions to complex medical challenges. By manipulating materials at the nanoscale level, scientists and bioengineers have unlocked a realm of possibilities for targeted drug delivery, imaging, and diagnostics. This cutting-edge technology holds immense potential to transform the way we diagnose and treat diseases, […]

In the realm of biotechnology, six companies stand at the forefront of a transformative era, driving the mRNA revolution with unparalleled innovation and unwavering commitment. Through a harmonious blend of scientific prowess, technological advancement, and visionary leadership, these companies have not only revolutionized the landscape of medicine but have also redefined the very essence of […]

In a realm where the flickering flame of hope for ophthalmic breakthroughs dances with cautious optimism, Inflammasome Therapeutics recently unveiled the enigmatic results of their maiden voyage into the uncharted waters of the K8 GA trial. Like a whispered secret carried by the wind, the news of K8’s remarkable ability to diminish the growth of […]

Alnylam Pharmaceuticals, a leading player in RNA interference therapeutics, recently joined the prestigious Alliance for Genomic Discovery (AGD) alongside Illumina, Inc., and Nashville Biosciences, LLC. This partnership signifies a significant step towards leveraging a diverse clinical genomic dataset to drive precision medicine and accelerate drug target discovery. The AGD, with Alnylam as its newest member, […]

Protagonist Therapeutics, a clinical-stage biopharmaceutical company, has recently been under the magnifying glass of four analysts, each painting a unique perspective ranging from optimistic to pessimistic. These evaluations shed light on the company’s current standing and future potential in the competitive landscape of peptide therapeutics. Deciphering Analyst Ratings The evaluations of Protagonist Therapeutics by financial […]

Welcome to the exhilarating world of Protagonist Therapeutics, where groundbreaking advancements meet soaring stock prices and promising clinical trials. Let’s dive into the recent triumphs and future prospects of this innovative biotech company that is revolutionizing the treatment landscape. Protagonist Therapeutics: A Stock Market Sensation Protagonist Therapeutics has been making waves in the stock market, […]

Intellia Therapeutics, a pioneer in the realm of genetic therapeutics, has set the stock market ablaze with its recent developments, particularly the completion of the crucial Phase 3 HAELO trial. The company’s shares, under the ticker NTLA, have surged to unprecedented heights as it achieved a significant milestone and unveiled its key developmental roadmap. Unveiling […]

Lipid nanoparticles (LNPs) have revolutionized the field of drug delivery, particularly for RNA therapeutics. The successful development of LNPs for COVID-19 mRNA vaccines by Pfizer/BioNTech and Moderna has propelled the global market for LNPs to new heights. LNPs are now at the forefront of RNA therapeutics for genetic diseases, cancers, and immunotherapies. This article delves […]

In the realm of biopharmaceuticals, the surge in utilizing monoclonal antibodies (mAbs) has underscored the necessity for novel analytical techniques that can accurately scrutinize the physicochemical attributes of these intricate drugs. One crucial quality attribute (QA) for biopharmaceuticals is the higher order structure (HOS), pivotal for ensuring consistency in manufacturing, detecting variations from process alterations, […]

Get ready for a groundbreaking event in Boston, Massachusetts, from September 23-25, 2025, as Creative Biolabs takes center stage as one of the premier exhibitors at the 7th Exosome-based Therapeutic Development Summit. Unveiling Exosome Innovations Exosomes are the rising stars in drug delivery technology, offering unparalleled loading capacity and exceptional biocompatibility. However, challenges such as […]

Microbiome therapeutics have emerged as a revolutionary approach in the field of healthcare, aiming to leverage the vast potential of the human gut microbiome for therapeutic interventions. This innovative strategy involves the engineering of the gut microbiome through additive, subtractive, or modulatory therapies, utilizing a range of tools such as probiotics, bacteriophages, antibiotics, and microbial […]

Resolution Therapeutics, a cutting-edge biopharmaceutical company based in Edinburgh, has recently made strategic additions to its leadership team, appointing Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. The company is dedicated to pioneering revolutionary regenerative macrophage therapies aimed at treating inflammatory and fibrotic diseases. In a bold move towards advancing […]

Lunai Bioworks Inc.’s subsidiary, BioSymetrics Inc., in partnership with Brigham and Women’s Hospital, has been granted a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). This collaboration aims to develop a cutting-edge platform that merges artificial intelligence with zebrafish screening to expedite drug discovery for Alcohol Use Disorder (AUD). […]

Schizophrenia, a complex mental disorder affecting millions globally, presents a significant challenge due to its diverse symptomatology. While antipsychotic medications have traditionally targeted positive symptoms like delusions and hallucinations, addressing negative symptoms such as anhedonia and social withdrawal has remained a critical unmet need in schizophrenia management. However, a groundbreaking development in the form of […]

Quotient Sciences and CPI have joined forces in a groundbreaking collaboration aimed at advancing the development of RNA-based therapeutics. By combining their respective strengths, the two companies are poised to revolutionize the creation of mRNA drugs through the integration of cutting-edge technologies. At the core of this joint venture is the fusion of Quotient’s Translational […]

Mission Therapeutics, a cutting-edge biotech company, is at the forefront of revolutionizing formulation development in the pharmaceutical industry. Specializing in advanced technologies for insoluble compounds such as nanoemulsions, nanoparticles, and amorphous formulations, Mission Therapeutics is dedicated to overcoming challenges in drug delivery and efficacy. With a focus on precision and innovation, the company is paving […]

In the dynamic realm of global biopharmaceuticals, a wave of innovation is reshaping the landscape, particularly in the treatment of complex conditions like organ fibrosis and liver diseases. Among the emerging players in this transformative space is Gyre Therapeutics Inc., a forward-thinking biopharmaceutical company that has recently caught the eye of analysts for its groundbreaking […]

Oral delivery of messenger RNA (mRNA) therapeutics holds promise for providing noninvasive and self-administered treatments and vaccinations. However, the harsh conditions of the gastrointestinal (GI) tract pose challenges for the effective delivery of these therapeutics. In a recent study, researchers developed a novel capsule-based device called RNACap, specifically engineered for the oral delivery of liquid […]

Rakovina Therapeutics, a biopharmaceutical company at the forefront of cancer therapy development, proudly announced that their Chief Scientific Officer, Dr. Mads Daugaard, has been selected to present at the prestigious 13th Tuscany Retreat on Cancer Research and Apoptosis. This event, held in Tuscany, Italy, focuses on genetic profiling, resistance mechanisms, and innovative treatment strategies in […]

The landscape of oligonucleotide-based treatments, such as guide RNAs and siRNAs, is evolving towards increased complexity. This complexity poses significant challenges in effectively separating the desired products from impurities, impacting the purity, safety, and regulatory compliance of these therapeutics. Traditional purification methods like strong anion exchange (AX) and ion-pair reversed-phase (IPRP) chromatography are vital in […]

In the realm of drug treatments, especially those involving high-dose protein-based therapeutics, the limitation of being available solely as intravenous (IV) infusions poses significant challenges. These protein therapeutics necessitate delivery as dilute solutions to prevent protein aggregation and maintain stability, often requiring high doses for efficacy. Consequently, patients undergo time-consuming treatments, and healthcare infrastructure must […]

Pharmaceutical company Shield Therapeutics has experienced a significant boost in revenues and a narrowing of losses, primarily driven by the success of its iron deficiency-fighting tablets in the United States. The company, known for its product Accrufer in most territories and Ferracru in Europe, has witnessed a substantial increase in group revenues, prescription sales, and […]

Protagenic Therapeutics Inc (PTIX) has set the stock market abuzz with excitement as its shares surged by over 100% following a significant clinical milestone announcement. The company has achieved a key advancement in its Phase 1 clinical trial for PT00114, a revolutionary hormone therapy designed to address stress and mood disorders such as anxiety, depression, […]

Daewoong Pharmaceutical and Daewoong Therapeutics have made a groundbreaking advancement in drug delivery technology with their semaglutide microneedle patch, boasting over 80% relative bioavailability compared to injectable formulations in a recent pilot study. This achievement, made possible by the CLOPAM® drug-delivery platform, marks a significant leap forward in enhancing delivery efficiency for high-dose biologics. The […]

In the realm of stock trading, understanding momentum signals is crucial for investors seeking short-term trading opportunities. Benzinga’s rankings system provides essential insights into stocks’ momentum, growth, value, and quality. Among the recent noteworthy momentum movers are three stocks that have exhibited significant shifts in momentum, presenting potential trading opportunities. BioXcel Therapeutics Inc. has emerged […]

RNA therapeutics have emerged as a promising avenue in the realm of personalized medicine, offering significant potential in combating various diseases, notably cancer. Circular RNA (circRNA) and Self-Amplifying RNA (saRNA) are two key areas of therapeutic RNA exploration, with their unique characteristics showing promise in therapeutic development. Optimizing RNA manufacturing processes is crucial for the […]

Porosome Therapeutics has made groundbreaking strides in Alzheimer’s disease research, with notable achievements such as FDA validation of organoid-based research and the development of innovative therapies targeting Tau proteins. The company’s approach focuses on altering disease progression rather than merely alleviating symptoms. Through their unique “Reprogram, Restore, and Rescue” methodology, Porosome Therapeutics introduces healthy porosomes […]

Travere Therapeutics (TVTX) is set to release its quarterly earnings report on August 6, 2025. Analysts are predicting an earnings per share (EPS) of $-0.12 for the company. Investors are eagerly awaiting this announcement, hoping for results that exceed expectations and positive guidance for the upcoming quarter. It’s important to note that guidance provided by […]

CytomX Therapeutics (NASDAQ: CTMX) has delivered substantial returns to its shareholders, boasting a remarkable 79% increase in share price over the past year. While investing in exchange-traded funds is a common approach, selecting individual stocks like CytomX Therapeutics has proven to yield above-average returns. The company’s stock performance has significantly outpaced the market, with a […]

CytomX Therapeutics has recently been evaluated by four analysts, each providing a unique perspective on the company’s stock performance over the past three months. These evaluations range from bullish to bearish, offering a diversified view on the future prospects of CytomX Therapeutics (CTMX). The 12-month price targets set by these analysts indicate an average target […]

Frazier Life Sciences recently closed a new venture capital fund for startup creation and investing in early-stage biotechnology companies, raising an impressive $1.3 billion. This move solidifies Frazier’s position as one of the most active venture investors in the biopharma sector. With a focus on oncology, Frazier has funded promising drugmakers like Alentis Therapeutics, Tubulis, […]

Get ready, Maryland! Nearly 100 cannabis dispensaries across the state are gearing up to make history by offering marijuana to all adults over the age of 21. Starting this Saturday, residents can legally purchase cannabis products for recreational use. Ember Therapeutics is at the forefront of this exciting development, providing high-quality products to meet the […]